Hemostemix (TSE:HEM) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hemostemix Inc. has entered into a definitive Manufacturing Services Agreement with CytoImmune Therapeutics, marking the restart of production for its cardiovascular stem cell therapy, ACP-01, with initial sales expected to make the company self-funding. The agreement, involving a share issuance to CytoImmune, will also cover the production costs for the first batch of commercial treatments, targeting sales of $1.1 million. This strategic partnership aims to deliver life-changing treatments for patients with severe cardiovascular diseases while ensuring significant cash flow for Hemostemix shareholders.
For further insights into TSE:HEM stock, check out TipRanks’ Stock Analysis page.